688192 迪哲医药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-70.977-162.312-84.976-34.871-37.827
总资产报酬率 ROA (%)-24.815-52.624-61.913-30.491-34.110
投入资产回报率 ROIC (%)-30.024-64.724-71.379-33.498-36.913

边际利润分析
销售毛利率 (%)95.68197.41196.478--12.420
营业利润率 (%)-99.420-261.545-1,213.308---6,512.850
息税前利润/营业总收入 (%)-95.548-254.688-1,207.359---6,441.487
净利润/营业总收入 (%)-99.429-261.087-1,213.419---6,512.850

收益指标分析
经营活动净收益/利润总额(%)111.199106.098104.851106.708101.841
价值变动净收益/利润总额(%)-3.183-1.538-2.033-5.730-0.353
营业外收支净额/利润总额(%)0.000-0.1760.0000.0000.000

偿债能力分析
流动比率 (X)2.4681.2722.0305.9289.964
速动比率 (X)2.4231.2161.9785.9089.964
资产负债率 (%)51.14888.36043.28815.53510.304
带息债务/全部投入资本 (%)41.10482.01127.8060.5610.660
股东权益/带息债务 (%)139.66417.448242.22217,006.87214,625.948
股东权益/负债合计 (%)95.29112.758131.011543.703870.537
利息保障倍数 (X)-24.679-39.802-202.96590.190-90.264

营运能力分析
应收账款周转天数 (天)35.59837.778189.449--252.938
存货周转天数 (天)440.6261,305.8151,597.977--0.000